AzTrials
AzTrials

Pancreatic AdenocarcinomaNCT04902352

The DISSECT Study: Effect of Peri-aDventItial SMA diSsECtion on Margin sTatus During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

A study testing No Periadventitial dissection of the SMA and Periadventitial dissection of the SMA in people with Pancreatic Adenocarcinoma, run by University Hospital Birmingham NHS Foundation Trust at 1 site in United Kingdom.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pancreatic Adenocarcinoma
What is being tested?
No Periadventitial dissection of the SMA and Periadventitial dissection of the SMA
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
102 participants
Where
1 siteUnited Kingdom
Study dates
6 Apr 2021to 6 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • All adult (≥ 18 years old) patients with a non-metastatic (based on NCCN definition) on imaging pancreatic tumour of the head or uncinate process treated with a pancreaticoduodenectomy

Who cannot join

  • All paediatric patients (< 18 years old)
  • Patients that cannot provide consent
  • All borderline, locally advanced and metastatic pancreatic tumours on imaging (based on NCCN criteria)
  • All patients with a cytological or histological diagnosis of cholangiocarcinoma, ampullary and duodenal carcinoma
  • All patients with benign disease or dysplasia with no evidence of malignancy

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • University Hospitals Birmingham NHS Foundation Trust

    Birmingham, County (Optional), B15 2GW

Other trials in United Kingdom

About this study

Official title: Effect of Peri-adventitial SMA Dissection on Margin Status During Pancreaticoduodenectomy for Resectable Pancreatic Cancer

There is a high rate of R1 resection following patients undergoing pancreaticoduodenectomy for pancreatic cancer. The most commonly positive margin is the SMA. Peri-adventitial dissection has been proposed as an effective method of achieving R0 margins. There is lack of standardisation of the proposed technique and no grade 1 evidence to support routine use of this technique.

The goal of this randomised controlled trial is to investigate the role of routine peri-adventitial dissection on the SMA margin status.

Read the detailed description

Pancreatic cancer is the 4th cause of cancer death in Europe. With the existing treatments the overall 5-year survival remains 8%. For patients with non-metastatic disease, many are conventionally judged unresectable with just 10-20% eligible for upfront surgery and a 5-year survival of 10-30%. Microscopically positive margins (R1) have been associated with poorer survival of patients undergoing pancreaticoduodenectomy. The incidence of R1 varies between 16-79% in the published literature and the median survival for patients undergoing R0 resections is between 19-21 months versus 9-13 months for patients undergoing R1. Therefore, to investigate strategies to decrease the rate of R1 resection is crucial to significantly improve the patient survival1.

The SMA margin is positive in 47-77% of these resections, even when the margin is "clear" on the pre-operative staging CT2,4. Many different techniques are in practice and have been described for this part of the pancreaticoduodenectomy procedure, including the use of diathermy and ties, energy devices such as Ligasure, and staplers. The main denominator is staying close to the SMA and removing the so called "mesopancreas"3.Peri-adventitial arterial dissection is a technique that has been a commune practise in several pancreatic centres and has been proposed as an effective surgical technique to achieve R0 margins. On the other hand, SMA dissection may theoretically increase the risk of acute haemorrhage, vascular injury, and thrombosis, development of pseudo-aneurysms or persistent chyle leak due to the extensive lymphoneural dissection. Furthermore, the published evidence reveal variability in the definition of a "positive margin", as well as the lack of accurate description of the surgical technique in the majority of the studies, with only about 25% of the studies reporting the use of the technique4. Moreover, none of the published studies have documented standardisation in the use of the technique with regards to the extent of the periadventitial dissection on the SMA, longitudinally and circumferentially.

In the University Hospitals of Birmingham NHS Trust, pancreatic surgery is centralised in Queen Elizabeth Hospital. Peri-adventitial dissection is selectively performed in cases where there is a close relation of the tumour to the arteries in an effort to achieve an R0 resection. Routine practice of peri-adventitial dissection during pancreaticoduodenectomy for resectable tumours has been performed in a subset of patients based on surgeon's preference. The results suggest a R1 rate of 20%, with SMA margin positivity 5%, compared to a rate of 44% margin positivity within the unit, with 54% SMA R1 rate. Furthermore, complication rates are comparable to the average described by the unit's results and published literature (20.8% of grade B and above complications as per the Clavien-Dindo classification). More specifically, there have been no incidences of vascular related injury or complication related to the technique; or persistent chyle leak (one episode of chyle leak grade A recorded that was managed conservatively).

The goal of this prospective study is to investigate the role of routine peri-adventitial dissection on the SMA margin status. Primary outcome is SMA margin status. Secondary outcomes are: length of stay, complications, overall survival, disease free survival and adjuvant treatment uptake.

This will be a two arm, randomised 1:1 (periadventitial dissection : no periadventitial dissection) study. A pilot phase will determine feasibility to proceed with the rest of the trial and to determine:

  1. Feasibility of patient recruiting and randomisation
  2. Feasibility and reproducibility of the technique
  3. Feasibility of use of intraoperative photography
  4. Intraoperative and postoperative complication rate and severity (Clavien-Dindo classification)
  5. Positive SMA margin status rate Feasibility criteria to be met in order to proceed with the rest of the trial:
  6. Recruitment of at least 20 patients in 6 months (both arms)
  7. Periadventitial dissection technique to be performed in at least 80% of the randomised patients to that arm as documented by intraoperative photography
  8. Increase in the complication rate no more than 10%

For the full trial a sample size of 51 patients per arm has been based on a margin positivity of 44%, based on the unit's results, and expected 60% reduction (expected R1 18%) at power 80% (type A error 0.05).

Being tested
No Periadventitial dissection of the SMA, Periadventitial dissection of the SMA
Keywords
pancreatic cancer, SMA dissection, Superior mesenteric artery, margin status
Medical subject headings
Pancreatic Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No Periadventitial dissection of the SMAProcedure or surgery

    lymphoneural tissue around SMA left intact

  • Periadventitial dissection of the SMAProcedure or surgery

    For the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process. In the presence of an accessory or replaced right hepatic artery the peri-adventitial dissection should also be carried out around this vessel as well.

Study groups in NCT04902352
Study groupRoleWhat they receive
Periadventitial dissectionExperimentalFor the patients randomised for peri-adventitial dissection the right side of the SMA should be completely clear from lymphoneural tissue for at least 180 degrees on right side and from "angle" of the artery to the level of inferior border of the uncinate process.
Receives: Procedure: Periadventitial dissection of the SMA
NO periadventitial dissectionActive comparatorFor patients randomised to NO peri-adventitial dissection, the lymphoneural tissue around the SMA should be left intact
Receives: Procedure: No Periadventitial dissection of the SMA

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SMA margin status

    Rate of R0 resection (defined as no tumour within 1mm from the SMA margin)

    Measured: Recorded at histological examination estimated 2 weeks post-operatively

Secondary outcomes (5)
  1. Length of stay

    Number of days to discharge (day 0 being the day of the operation)

    Measured: Recorded at patient discharge (monitored by research team) and analysed at an expected time frame of 2 years (study end)

  2. Complications

    categorised by clavien-dindo (grade 1 to 5, higher score = worse)

    Measured: 90 days

  3. adjuvant treatment

    percentage of patients receiving adjuvant chemotherapy, type and duration.

    Measured: within 1 year of surgery

  4. Overall survival

    The length of time (in months) from day of diagnosis to death or last follow up

    Measured: Analysis at 5 years from start of trial

  5. Disease free survival

    length of time (in months) from day of resection until diagnosis of recurrence or last follow up

    Measured: Analysis at 5 years from start of trial

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 May 2021
  2. Study start6 Apr 2021
  3. Primary completion6 Oct 2026 (estimated)
  4. Study completion6 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomised Control Trial
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
102 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04902352
Sponsor's protocol ID
RRK6941
Status last verified
Nov 2025
First submitted
13 May 2021
Last updated
18 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing No Periadventitial dissection of the SMA and Periadventitial dissection of the SMA in people with Pancreatic Adenocarcinoma, run by University Hospital Birmingham NHS Foundation Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 18 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SMA margin status (time frame: Recorded at histological examination estimated 2 weeks post-operatively). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in